XLO earnings date and last-quarter result: next report 2026-08-13, last quarter beat, P/E -1.54. Updated 2026-07-23.
Xilio Therapeutics (XLO) Research Hub
Xilio Therapeutics (XLO) trades on NASDAQ, US in the Healthcare (Biotechnology) sector. As of 2026-10-26, shares last closed at 7.31 USD (-3.43%), in a range — insufficient history for 200-DMA. Valuation: trailing P/E -1.54, market cap 0.06B. This hub links to the full technical, earnings and options research available for XLO.
Last updated 2026-10-26 · Source: end-of-day prices (adjusted); indicators computed by SniperIQ
| Sector | Healthcare (Biotechnology) |
|---|---|
| Exchange | NASDAQ, US |
| Last close | 7.31 USD (-3.43%) |
| 52-week range | 7.05 USD – 9.9 USD |
| Trend regime | Range |
| 14-day RSI | 19.7 (Oversold) |
| Trailing P/E | -1.54 |
| Market cap | 0.06B |
| Dividend yield | 0.00% |
| Next earnings | 2026-08-13 |
Available research for XLO
Covered Call on XLO: how it works, illustrative setup around the real 7.31 USD price, max profit/loss, breakeven and when to use it. Educational.
Iron Condor on XLO: how it works, illustrative setup around the real 7.31 USD price, max profit/loss, breakeven and when to use it. Educational.
Protective Put on XLO: how it works, illustrative setup around the real 7.31 USD price, max profit/loss, breakeven and when to use it. Educational.
XLO technical analysis: range, last 7.31 USD, RSI 19.7, 52w range 7.05 USD–9.9 USD, real support/resistance. Updated 2026-10-26.
More on SniperIQ
Frequently asked questions
What sector is XLO in?
Xilio Therapeutics (XLO) is classified under Healthcare (Biotechnology), listed on NASDAQ, US.
Is XLO in an uptrend or downtrend?
As of 2026-10-26, XLO is in a range — insufficient history for 200-DMA. See the full technical research page for support and resistance levels.
What is XLO's trailing P/E ratio?
XLO's trailing P/E is -1.54, with a market cap of 0.06B. See the earnings research page for full valuation detail.
When does XLO next report earnings?
XLO is next scheduled to report earnings on 2026-08-13.